Resumo:
En
|
Texto:
En
|
PDF:
En
SUMMARY OBJECTIVE: Cisplatin, a widely used anticancer agent, induces hepatotoxicity alongside organ damage. Understanding Cisplatin's toxicity mechanism and developing preventive measures are crucial. Our study explores Myricetin, a flavonoid, for its protective effects against Cisplatin-induced hepatotoxicity. METHODS: In our study, a total of 32 Wistar albino male rats were utilized, which were categorized into four distinct groups: Control, Myricetin, Cisplatin, and Myricetin+Cisplatin. For the histological assessment of hepatic tissues, hematoxylin–eosin and periodic acid Schiff staining were employed, alongside immunohistochemical measurements of TNF-α, interleukin-17, and interleukin-6 immunoreactivity. Additionally, aspartate transaminase and alanine transaminase values were examined by biochemical analysis. RESULTS: In the histological evaluation of the tissues, a normal healthy cell structure and a strong periodic acid Schiff (+) reaction were observed in the hepatocyte cells in the tissues of the Control and Myricetin groups, while intense eosinophilia, minimal vacuolization, congestion, and sinusoidal expansions were observed in the hematoxylin–eosin stainings, and a decrease in the positive reaction in the periodic acid Schiff staining was observed in the Cisplatin group. Consistent with these histological findings, an increase in TNF-α, interleukin-17, and interleukin-6 expressions (p<0.0001) and a concomitant increase in aspartate transaminase and alanine transaminase values were observed in the Cisplatin group. In the group protected by Myricetin, a significant improvement was observed in all these histological and biochemical values. CONCLUSION: Cisplatin induces notable histopathological alterations in the liver. In this context, Myricetin exhibits the potential to alleviate Cisplatin-induced damage by modulating histological parameters and biochemical processes. OBJECTIVE agent Cisplatins s crucial flavonoid Cisplatininduced induced METHODS 3 utilized groups MyricetinCisplatin Myricetin+Cisplatin hematoxylineosin hematoxylin eosin employed TNFα, TNFα TNF α, α TNF-α interleukin17, interleukin17 interleukin 17, 17 interleukin-17 interleukin6 6 interleukin- immunoreactivity Additionally analysis RESULTS + (+ eosinophilia vacuolization congestion stainings findings p<0.0001 p00001 p 0 0001 (p<0.0001 CONCLUSION liver context processes interleukin1 1 interleukin-1 ( p<0.000 p0000 000 (p<0.000 p<0.00 p000 00 (p<0.00 p<0.0 p00 (p<0.0 p<0. p0 (p<0. p<0 (p<0 p< (p< (p